Holiday Notice: Expect delayed shipping. Orders ship 4/6.
FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION.

GLP-1 C + GLP-1 S — Published Research

Reviewed by: Dr. Sarah Chen, PharmD| Last updated: March 8, 2026|For laboratory reference only

← Back to GLP-1 C + GLP-1 S product page

Research Library

Published research on these compounds — for educational purposes only

C Mechanism of Action at Amylin Receptors

C is an acylated long-acting analog of amylin that binds to amylin receptor subtypes (AMY1 and AMY3) and calcitonin receptors. Its mechanism of action involves activation of receptor activity-modifying proteins (RAMPs) complexed with the calcitonin receptor, triggering intracellular cAMP signaling cascades. The C18 fatty diacid modification enables non-covalent albumin binding, extending the pharmacokinetic half-life in preclinical models. Research compound — not for human use.

Hay DL et al. “Amylin: Pharmacology, Physiology, and Clinical Potential.” Pharmacol Rev. 2015. PubMed

GLP-1 S GLP-1 Receptor Binding and Signaling

GLP-1 S is a GLP-1 receptor agonist featuring an Aib8 substitution and a C18 fatty diacid chain linked via a mini-PEG spacer at Lys26. It activates the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor, triggering Gαs-mediated cAMP accumulation. The structural modifications confer resistance to DPP-4 enzymatic degradation and enable strong albumin binding, resulting in an extended pharmacokinetic half-life. Research compound — not for human use.

Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and GLP-1 S.” Front Endocrinol. 2019. PubMed

Dual Amylin and GLP-1 Pathway Pharmacology

Research into the co-administration of amylin analogs with GLP-1 receptor agonists investigates the convergent signaling pathways in the area postrema, nucleus tractus solitarius, and hypothalamic nuclei. Both amylin and GLP-1 receptors signal through cAMP-dependent pathways in hindbrain neurons, with distinct receptor distributions suggesting complementary rather than redundant receptor engagement. Preclinical models have characterized the pharmacodynamic interactions between these two receptor systems. Research compound — not for human use.

Lutz TA. “The interaction of amylin with other hormones in the control of eating.” Diabetes Obes Metab. 2013. PubMed

Disclaimer: All research citations are provided for educational purposes only. These references describe findings from in vitro and animal model studies. This information does not constitute medical advice and should not be interpreted as endorsement of any specific application.

Reviewed by

Dr. Sarah Chen, PharmD

Research pharmacologist specializing in peptide therapeutics. Reviews published clinical data and pharmacological research for accuracy and completeness.

Editorial Review

Reviewed by Dr. Sarah Chen, PharmD and Dr. James Porter, PhD — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published peer-reviewed research for educational purposes only. It is not medical advice and does not constitute a recommendation for any specific compound or protocol.